Aventis SA

Industry:

Pharmaceuticals, Drug Manufacturing & Research

Description

Aventis (NYSE: AVE) is dedicated to improving life by treating and preventing human disease through the discovery and development of innovative prescription drugs for important therapeutic areas as well as human vaccines. Aventis Pasteur is the vaccine division within Aventis. In 2001, Aventis generated sales of € 17.7 billion, invested € 3 billion in research and development and employed approximately 75,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France.

View More Statistics

Site Statistics

Monthly Unique Visitors:	1,222
Site Rank:	954,428
Trust Rating:	Neutral
Stats by

News Archive

Sanofi-Aventis SA.(CORPORATE)(patent infringement cases of Sanofi-Aventis SA. vs. Sandoz Inc.,) MondayMorning; 9/14/2009 SANOFI-AVENTIS SA. , France's biggest drugmaker, won an appeals court ruling that revives its efforts to block copies of the colon cancer drug... ...more

Sanofi-Aventis SA.(CORPORATE)(acquisition of Shantha Biotechnics )(Brief article) MondayMorning; 8/3/2009 SANOFI-AVENTIS SA. , France's biggest drugmaker, agreed to take control of Shantha Biotechnics in an acquisition valuing the Indian vaccine maker... ...more

Sanofi boosts drug development with Fovea; Merrimack.(TOP STORIES)(Fovea Pharmaceuticals SA)(Merrimack Pharmaceuticals Inc)(Sanofi-Aventis SA)(Brief article) MondayMorning; 10/5/2009 Sanofi-Aventis SA, under pressure to expand as rivals merge and top drugs face competition, agreed to buy eye specialist Fovea Pharmaceuticals... ...more